40 peer-reviewed studies · Evidence score: 9/10
Stehle P et al. • Critical Care Medicine (2020)
Parenteral glutamine supplementation reduced infectious complications and hospital length of stay in ICU patients.
Yang M et al. • BioMed research international (2022)
Optimizing HU adherence has the potential to improve HRQOL in patients with SCD in addition to reducing healthcare utilization and improving treatment satisfaction.
Brami C et al. • Critical reviews in oncology/hematology (2016)
Electroacupuncture was not superior to placebo.
Yassin M et al. • Blood reviews (2025)
A pivotal phase III study of l-glutamine showed that patients treated with l-glutamine had a 25 % reduction in pain crises and 33 % fewer hospital days compared to placebo. l-glutamine was generall...
Pu J et al. • Molecular psychiatry (2021)
This meta-analysis examined the effects of Acetyl-L-Carnitine.
Ramezani Ahmadi A et al. • Nutrients (2019)
Glutamine supplementation attenuated exercise-induced immune suppression markers including reduced upper respiratory tract infections in athletes.
Liang S et al. • Cellular and molecular life sciences : CMLS (2022)
The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Hou XW et al. • Investigative ophthalmology & visual science (2021)
This review summarizes potential biomarkers and metabolic pathways, providing insights into new pathogenic pathways for this microvascular complication of diabetes.
Thom H et al. • BMJ open (2020)
This NMA provides preliminary evidence comparing the efficacy of crizanlizumab with other treatments for VOC prevention.
Gholamalizadeh M et al. • JPEN. Journal of parenteral and enteral nutrition (2022)
This study identified that glutamine supplementation might have an important effect on CRP in acute conditions and no significant effect on IL-6 and TNF-α in acute conditions.
Ripani U et al. • Medical archives (Sarajevo, Bosnia and Herzegovina) (2022)
According the scientific literature nutraceutical therapy associated with dexamethasone can reduce the expression of Interlukina-6(IL-6) and myalgia due to COVID-19.
Burgess LC et al. • Nutrients (2018)
Optimizing nutritional status pre-operatively may help manage the surgical stress response, with a particular benefit for undernourished, frail, or elderly individuals.
Wen S et al. • Acta odontologica latinoamericana : AOL (2023)
Dentoxol mouthwashes, Plantago major extract, thyme honey extract, zinc oxide paste, vitamin B complex combined with GeneTime, and the consumption of L-glutamine are effective in diminishing the severity of OM.
Han J et al. • Pharmacotherapy (2020)
Current available data suggest crizanlizumab is a promising agent to reduce VOC in patients with SCD.
Bührer C et al. • Pediatric research (2020)
Thus, selected food components may help to improve outcomes in preterm infants.
Cieri-Hutcherson NE et al. • Pharmacotherapy (2019)
Based on the results of a systematic review, l-glutamine may be considered for patients unable to receive hydroxyurea or in addition to hydroxyurea for reduction in VOC and associated pain.
Sadaf A et al. • Clinical pharmacokinetics (2024)
We report the first pharmacokinetic study of multiple-dose, long-term oral L-glutamine therapy and the first population pharmacokinetic analysis of L-glutamine for sickle cell disease.
Norouzi M et al. • Trials (2022)
The present study showed that perioperative supplementation with a combination of Gln, Arg, and HMB enhances the recovery, reduces myocardial injury, and decreases the time of hospital and ICU stay in cardiac surgery patients.
Bloomer RJ et al. • Nutrients (2024)
Our results indicate the product was well-tolerated at all dosing levels and no significant adverse changes occurred in any of the test parameters compared to the placebo group, indicating relative safety of ingestion over a 4-week treatment period, at the volumes used, and outside the context of physical stress.
Tsujimoto T et al. • Nutrients (2023)
These findings indicate that L-glutamine does not influence the survival of patients with locally advanced head and neck cancer receiving chemoradiotherapy.